Close

Aeglea BioTherapeutics' (AGLE) AEB1102 Receives FDA Fast Track Designation for Treatment of Patients with Hyperargininemia

May 23, 2016 4:01 PM EDT Send to a Friend
Aeglea BioTherapeutics, Inc., (NASDAQ: AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login